This Clinical Reference Group (CRG) covers medical genetics. Diseases with a genetic component are estimated to affect at least 5–6% of the population.
Medical genetics is divided into two main service areas and both cover children and adults:
- Clinical genetics has a key role in the diagnosis and management of multisystem genetic disorders
- Laboratory genetics services provide molecular and/or cytogenetic testing. This covers diagnostic testing, carrier testing, prenatal and pre-symptomatic testing for a range of conditions.
Chair: Dr Frances Elmslie, Consultant Clinical Genetics, St George’s University Hospitals NHS Foundation Trust.
Ann Dalton, North
Fiona Lalloo, North
Richard Sandford, Midlands & East
Susan Price, Midlands & East
Vishakha Tripathi, London
Richard Thompson, London
Katherine Lachlan, South
Eileen Roberts, South
Jayne Spink, Patient & Public Voice
Louise Coleman, Patient & Public Voice
Frank Jones, Patient & Public Voice
Anthony Prudhoe, Lead Commissioner, firstname.lastname@example.org
A key part of the CRG’s work is the delivery of the ‘products’ of commissioning. These are the tools used by the 10 Hub Commissioning Teams to contract services on an annual basis.
Service specifications are important in clearly defining the standards of care expected from organisations funded by NHS England to provide specialised care. The specifications have been developed by specialised clinicians, commissioners, expert patients and public health representatives to describe both core and developmental service standards. Core standards are those that all funded providers should be able to demonstrate, with developmental standards being those which may require further changes in practice over time to provide excellence in the field.
The following service specifications fall within the scope of this CRG:
- Medical Genetics (All Ages)
- Stickler syndrome diagnostic service (Children)
- Complex Neurofibromatosis Type 1 Service (All Ages)
- Neurofibromatosis Type 2 Service (All Ages)
A commissioning policy is a document that defines access to a service for a particular group of patients. A NICE Technology Appraisal Guideline on the same topic will replace, or be incorporated into, a commissioning policy as appropriate. These are important documents that are developed to ensure consistency in access to treatments nationwide.
The following policies fall within the scope of this CRG: